indomethacin treatment for each quartile. Results: The relative treatment effects of prophylactic indomethacin on severe IVH did not vary based on the predicted risk of severe IVH: quartile 1: aOR 0.68 (95% confidence interval [CI] 0.19-2.37); quartile 2: aOR 0.61 (95% CI 0.27-1.42); quartile 3: aOR 0.63 (95% CI 0.31-1.31); quartile 4: aOR 0.58 (95% CI 0.32-1.05). The relative treatment effect of prophylactic indomethacin on death or NDI did not vary significantly between quartiles. Conclusions: These findings do not support selective prophylactic indomethacin treatment to improve longterm outcomes of ELBW infants at high risk for severe IVH.
Introduction
Severe brain injury is an important prognostic indicator of death or neurodevelopmental impairment (NDI) in extremely low birth weight (ELBW) infants [1] . In the Trial of Indomethacin Prophylaxis in Preterms (TIPP), prophylactic indomethacin reduced the risk of severe (grade III or IV) intraventricular hemorrhage (IVH) from 13 to 9% (adjusted odds ratio [aOR] 0.6, 95% confiKeywords Extremely low birth weight infants · Brain injury · Indomethacin · Neurodevelopmental disability Abstract Background: Prophylactic indomethacin reduces the risk of severe intraventricular hemorrhage (IVH) but does not reduce death or neurodevelopmental impairment (NDI) among extremely low birth weight (ELBW) infants. Some investigators have suggested that prophylactic indomethacin may have a greater treatment effect on severe IVH among infants at high risk for severe IVH. Objective: To determine whether the relative treatment effects of prophylactic indomethacin on severe IVH and the composite outcome of death or NDI vary based on the risk of severe IVH. Methods: Post hoc analysis of the Trial of Indomethacin Prophylaxis in Preterms (TIPP). We generated a model to predict the risk for severe IVH based on gestational age, birth weight, antenatal steroids, delivery mode, outborn status, sex, and 5-min Apgar score, and we divided the TIPP participants into risk quartiles. We used logistic regression to determine the adjusted odds ratios (aOR) of severe IVH and death or NDI based on dence interval [CI] 0.4-0.9) but did not reduce the risk of the composite outcome death or NDI (aOR 1.1, 95% CI 0.8-1.4) [2] .
Some investigators have suggested that prophylactic indomethacin may have a greater treatment effect on severe IVH among infants at high risk for severe IVH [3] [4] [5] . Using clinical characteristics that are available at or soon after birth, these authors developed predictive models for severe IVH that would allow for targeted prophylactic indomethacin therapy among high-risk infants [3, 4] . We sought to determine whether the relative treatment effects of prophylactic indomethacin on severe IVH or the composite outcome of death or NDI vary based on the baseline risk of severe IVH in ELBW infants.
Methods
This was a post hoc analysis of the TIPP trial (Clinicaltrials.gov identifier NCT00009646) [2] . Briefly, in the TIPP study 1,202 preterm infants with birth weight between 500 and 999 g were randomly assigned to either prophylactic indomethacin or placebo treatment soon after birth, with a primary outcome of death or NDI at 18 months' corrected age. We used Stata version 14.0 (StataCorp, College Station, TX, USA) to develop a predictive model for severe IVH risk among control infants with IVH outcome ascertainment. The model included previously published covariates by Singh et al. [3] : gestational age, birth weight, antenatal steroids, delivery mode, outborn status, sex, and 5-min Apgar score. These covariates were well balanced between the intervention and control arms of the parent TIPP trial [2] . We used the same covariates but developed our own model for the present analysis because the model developed by Singh et al. [3] included infants up to 34 weeks' gestation, who were more mature than the TIPP population [2] .
Using this model, we calculated the predicted risk of severe IVH for each TIPP participant, and we used these values to generate quartiles of predicted risk for severe IVH within the entire TIPP population. We sought to determine whether the treatment effect of prophylactic indomethacin on severe IVH varies based on baseline IVH risk using a logistic regression model with an interaction term (indomethacin treatment × predicted risk quartile), after adjustment for center and multiple gestation. A significant interaction term would indicate that the indomethacin treatment effect varies based on the baseline risk of severe IVH. We used logistic regression to determine the aOR of severe IVH based on indomethacin treatment for each predicted risk quartile, adjusting for center and multiple gestation. We repeated this analysis for the composite outcome of death or NDI, adjusting for center, multiple gestation, and maternal education.
We used the original TIPP definitions for all exposures and outcomes [2] . Results with p < 0.05 were considered statistically significant. TIPP was conducted with local Institutional Review Board approvals and parental informed consent for all enrolled infants.
Results
The predicted risk of severe IVH was calculated for 1,196/1,202 TIPP participants. The remaining 6 infants were excluded due to missing 5-min Apgar scores. The numbers of infants in the indomethacin and placebo groups were similar across risk quartiles (Table 1) .
In multivariable logistic regression, the adjusted interaction term for indomethacin and predicted IVH risk was not significant for the outcome of severe IVH (p = 0.76) or death or NDI (p = 0.11). The relative treatment effects of prophylactic indomethacin on the outcomes of severe IVH and death or NDI did not vary significantly based on the baseline risk of severe IVH (Table 2 ; Fig. 1 ).
Discussion
Although prophylactic indomethacin reduces the risk of severe IVH, it does not reduce the risk of death or NDI in extremely preterm infants [6] . Despite this, some investigators promote a targeted approach to indomethacin prophylaxis among infants at highest risk for severe IVH [3] [4] [5] . We undertook this analysis to determine whether the relative treatment effects of prophylactic indomethacin vary based on the baseline risk of severe IVH for the following 2 outcomes: severe IVH and death or NDI. We found little evidence that the relative effects of prophylactic indomethacin therapy differ for either of these outcomes in ELBW infants based on the predicted risk of severe IVH.
The aOR for severe IVH were similar for all 4 risk quartiles in this study. In addition, the adjusted interac- 185 tion term was not statistically significant. These findings indicate that the relative treatment effect of prophylactic indomethacin on severe IVH does not vary based on the baseline risk of severe IVH.
However, the absolute treatment effects of prophylactic indomethacin on severe IVH are dependent on the baseline rate of severe IVH in a given population. Although no aOR for any quartile was statistically significant, our study results provide a useful illustration of this concept. As an example, the absolute risk reduction for severe IVH in the lowest risk quartile was 1.4%, which corresponds to a number needed to treat to prevent severe IVH of 71. In contrast, the baseline rate of severe IVH was much higher in the highest risk quartile. In this quartile, the absolute risk reduction was 8.9%, for a number needed to treat to prevent severe IVH of 11.
There were no significant differences in the rate of death or NDI between treatment groups for any risk quartile in our study. These results are consistent with previous findings that prophylactic indomethacin does not improve neurodevelopmental outcomes for ELBW infants [2, 6] , even among high-risk preterm infants.
We acknowledge that the TIPP trial was published in 2001, potentially limiting generalizability. In addition, we developed our predictive model for severe IVH using previously published covariates from a validated model, but our model was not validated in an external cohort. Last, the TIPP trial was not powered to detect a significant difference in NDI or death within quartiles of study participants.
Despite these limitations, the TIPP study population provides a unique opportunity to study the interaction 
